Physician profile
Reddog E Sina
NPI 1902035645
$1,156.70
in general payments reported to CMS, 2019-2025
22 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 87% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $75.69 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $302.07 | 2025 | |
| Biogen, INC. | $120.60 | 2024-2025 | Tysabri, Spinraza, Qalsody |
| Lilly USA, LLC | $81.06 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $79.54 | 2025 | Hyqvia |
| Ucb, INC. | $71.01 | 2025 | Briviact, Fintepla, Rystiggo |
| Vanda Pharmaceuticals INC. | $56.94 | 2025 | Ponvory |
| Lundbeck LLC | $49.64 | 2025 | Vyepti |
| Genentech USA, INC. | $45.45 | 2024-2025 | Ocrevus Zunovo |
| Argenx US, INC. | $43.15 | 2025 | Vyvgart Hytrulo |
| Pfizer INC. | $42.01 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $32.73 | 2025 | Austedo Xr |
| Eisai INC. | $30.28 | 2025 | |
| Sk Life Science, INC. | $23.55 | 2025 | |
| Tanabe Pharma America, INC. | $23.14 | 2025 | Radicava |
| Otsuka America Pharmaceutical, INC. | $22.56 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $21.99 | 2025 | Qutenza |
| Axsome Therapeutics, INC. | $21.55 | 2025 | Symbravo |
| Merz Pharmaceuticals, LLC | $20.96 | 2025 | Xeomin |
| Alexion Pharmaceuticals, INC. | $20.60 | 2025 | Ultomiris |
| Itf Therapeutics LLC | $18.62 | 2025 | |
| Aucta Pharmaceuticals, INC. | $14.78 | 2025 | Motpoly Xr |
| Owp Pharmaceuticals, INC. | $14.47 | 2025 | Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reddog Sina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.